Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2025-11-24 00:00:00 ET · period of report 2025-11-21 · accession 0001644975-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-24 | 2025-11-21 | MLYS | Congleton Jon | CEO, Dir | M - OptEx | $0.54 | +24.1K | 655.4K | +4% | +$13.0K |
| D | 2025-11-24 | 2025-11-21 | MLYS | Congleton Jon | CEO, Dir | M - OptEx | $0.00 | -24.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-21 | M | A | 24,082 | $0.54 | 655,387 | D | — | — | |
| 2 | Derivative | Stock Option | 2025-11-21 | M | D | 24,082 | $0.00 | 0 | D | $0.54 · — to 2031-03-11 | 24,082 Common Stock | (F1) Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. (F2) The stock option vested with respect to 25% of the underlying shares on March 12, 2022 and the remaining shares in 36 substantially equal monthly installments thereafter. |